Based on these results, the most recent guidelines recommend DOAC + P2Y12 inhibitors in patients with AF who undergo percutaneous coronary interventions with stenting for acute coronary syndrome [26]. The gene discussed is P2RY12; the disease is acute coronary syndrome.